In the meantime current gene therapies remain expensive and challenging to scale up because each patient’s batch of cells has ...

Citi analyst Mathieu Chevrier maintained a Buy rating on CSL (CMXHF – Research Report) today and set a price target of A$345.00. The ...

Today, CSL – including our three businesses: CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to ...

In an era where artificial intelligence (AI) is transforming industries and reshaping our daily lives, it is more important than ever to equip the next generation with the skills and knowledge to ...

Here's why CSL Limited (ASX: CSL) and these ASX 200 stocks could be great portfolio additions this week according to ...

In a report released yesterday, Shane Storey from Wilsons maintained a Hold rating on CSL (CMXHF – Research Report), with a price target ...

With reporting season all done and dusted for FY24, which ASX shares do our Foolish writers think came out on top? The post ...

Despite the availability of evidence-based treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), their use frequently results in incomplete recovery.1 Intravenous ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

It has been a good week for CSL Behring as it rolls out haemophilia B gene therapy Hemgenix, with positive reimbursement decisions in both the UK and Denmark. In the UK, health technology ...

It is one of the world's leading biotechnology companies, comprising the CSL Behring, CSL Vifor, and CSL Seqirus businesses. These are leaders in their fields of plasma therapies, iron deficiency ...